Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Calmy, Alexandra ^a   Balestre, Eric ^b,c   Bonnet, Fabrice ^b,c,d   Boulle, Andrew ^e   Sprinz, Eduardo ^f   Wood, Robin ^g   Delaporte, Eric ^h   Messou, Eugène ⁱ   McIntyre, James ^j   El Filali, Kamal M ^k   Schechter, Mauro ^l   Kumarasamy, N ^m   Bangsberg, David ⁿ   McPhail, Patrick ^o   Van Der Borght, Stefaan ^p   Zala, Carlos ^q   Egger, Matthias ^r   Thiébaut, Rodolphe ^b,c   Dabis, François ^b,c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g Gugulethu ART Programme   (South Africa)

^h INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

ⁱ Centre de Prise en Charge   (Côte d’Ivoire)

^j Perinatal HIV Research Unit   (South Africa)

^k IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^l Rio HIV Cohort   (Brazil)

^m YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

ⁿ Immune Suppression Syndrome Clinic   (Uganda)

^o HELEN JOSEPH HOSPITAL   (South Africa)

^p Heineken International   (Netherlands)

^q Prospective Evaluation in the Use and Monitoring of Antiretrovirals in Argentina (PUMA)   (Argentina)

^r UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

CD4 count; CD4 slope; HIV 1; HIV RNA threshold; Resource limited settings

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; RNA ANALYSIS; RNA REPLICATION; TREATMENT RESPONSE; VIRUS CELL INTERACTION; VIRUS INHIBITION;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; RNA, VIRAL;

EID: 84862754884     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-147     Document Type: Article

References (32)

1. Pujades-Rodriguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008, 22:1305-1312. 10.1097/QAD.0b013e3282fa75b9, 18580610.
2. Keiser O, Orrell C, Egger M, . Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. PLoS Med 2008, 5:e148. Erratum in: PLoS Med. 2008; 9:e195, 10.1371/journal.pmed.0050148, 2443185, 18613745, Swiss HIV Cohort Study (SHCS) and the International Epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA).
3. Keiser O, Tweya H, Boulle A, . ART-LINC of IeDEA Study Group Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009, 23:1867-74. 2956749, 19531928, ART-LINC of IeDEA Study Group.
4. Renaud-Théry F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B, Perriëns J. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS 2007, Suppl 4:S89-95.
5. UNAIDS epidemic update 2009, Available from http://www.unaids.org/en/Dataanalysis/Epidemiology/2009AIDSEpidemicUpdate/ (accessed on March 7th, 2011).
6. World Health Organization Antiretroviral therapy for HIV Infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach Available from http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf (accessed August 4th, 2011), World Health Organization.
7. Moore DM, Mermin J, Awor A, Yip B, Hogg RS, Montaner JS. Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 2006, 43:436-439. 10.1097/01.qai.0000243105.80393.42, 17019367.
8. Koenig SP, Kuritzkes DR, Hirsch MS, et al. Monitoring HIV in developing countries. BMJ 2006, 332:602-604. 10.1136/bmj.332.7541.602, 1397781, 16528087.
9. Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: A randomized trial. BMJ 2011, 343:d6792. 10.1136/bmj.d6792, 3213241, 22074711.
10. Mugyenyi P, Walker AS, Hakim J, Munderi P, Gibb DM, . DART Trial Team Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. Lancet 2010, 375:123-31. 2805723, 20004464, DART Trial Team.
11. Chang LW, Harris J, Humphreys E. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HVI in low-resource settings. Cochrane Database Syst Rev 2010, 4:CD008494.
12. Jourdain G, Ngo-Giang-Huong N, et al. PHPT-3: a randomized clinical trial comparing CD4 vs. viral load ART monitoring/Switching strategies in Thailand. 18th Conference on retroviruses and opportunistic infections, Boston 2011 Abstract 44.
13. Kouanfack C, Laurent C, Laborde-Balen G, . for the Stratall ANRS 12110/ESTHER Study Group HIV viral load, CD4 cell count, and clinical monitoring s. clinical monitoring alone for ART in rural hospitals in Cameroon: stratall ANRS 12110/ESTHER trial, a randomized non inferioirity trial. 18th Conference on retroviruses and opportunistic infections, Boston 2011 Abstract 45 LB, for the Stratall ANRS 12110/ESTHER Study Group.
14. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 version) Available from http://www.who.int/hiv/pub/arv/adult2010/en/index.html (accessed on 4th August, 2011), World Health Organization.
15. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents - January 10, 2011 available from http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (accessed on March 7th, 2011).
16. European AIDS Clinical Society guidelines, version 6.0, October 2011 European AIDS Clinical Society guidelines, version 6.0, October 2011 accessed on April 2d, 2012 http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6_english.pdf, European AIDS Clinical Society guidelines, version 6.0, October 2011.
17. PLATO collaboration Predictors of trends in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 2004, 364:51-62. 10.1016/S0140-6736(04)16589-6, 15234856, PLATO collaboration.
18. Murri R, Cozzi-Perri A, Cicconi P, . for the Icona study group Is moderate HIV viremia associated with a higher risk of clinical progression in HIV positive people treated with HAART? Evidence from the Italian cohort of antiretroviral naïve patients study. J Acquir Immune Defic Syndr 2006, 41:23-30. 10.1097/01.qai.0000188337.76164.7a, 16340469, for the Icona study group.
19. Dabis F, Balestre E, Braitstein P, et al. Antiviral Therapy in Lower Income Countries (ART-LINC) Study Group. Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005, 34:979-86.
20. Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. Acquir Immune Defic Syndr 2009, 51:65-71.
21. Bourgeois A, Laurent C, Mougnutou R, et al. Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon. Antivir Ther 2005, 10:335-41.
22. Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, et al. When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study. AIDS 2001, 15:983-90. 10.1097/00002030-200105250-00006, 11399980.
23. ART LINC collaboration and ART-CC collaboration Mortality of HIV1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824. ART LINC collaboration and ART-CC collaboration.
24. Redd AD, Dabitao D, Bream JH, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A 2009, 106:6718-23. 10.1073/pnas.0901983106, 2667149, 19357303.
25. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, . EuroSIDA Study Group Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009, 200:687-97. 10.1086/604731, 19604043, EuroSIDA Study Group.
26. Seyler C, Adje-Toure C, Messou E, et al. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007, 21:1157-1164. 10.1097/QAD.0b013e3281c615da, 2486349, 17502726.
27. Phillips AN, Pillay D, Garnett G, et al. Effect on transmission of HIV-1 resistance of timing of implementation of viral laod monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 2011, 25:843-850. 10.1097/QAD.0b013e328344037a, 21192233.
28. Cohen MS, Chen YQ, McCauley M, . HPTN 052 Study Team Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505. 10.1056/NEJMoa1105243, 3200068, 21767103, HPTN 052 Study Team.
29. Hoffmann CJ, Charalambous S, Sim J, et al. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis 2009, 49:1928-1935. 10.1086/648444, 2789416, 19911963.
30. Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008, 22:2097-2106. 10.1097/QAD.0b013e32830f97e2, 2597677, 18832873.
31. Keiser O, Tweya H, Braitstein P, et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010, 15:251-8. 10.1111/j.1365-3156.2009.02445.x, 2873139, 20003034.
32. Anglaret X, Minga A, Gabillard D, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012, 5:714-23.